GSK3B and melanoma: It was suggested that targeting Axin1 stability by post-translational modifications like phosphorylation by GSK-3β, PARsylation by tankyrase-1/2 (TNKS1/2), methylation by protein arginine methyltransferase 1 (PRMT1), and SUMOylation [193,204,205] could sensitize melanoma cells to TRAIL-based therapies [203].